^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    alsevalimab (FPA150)

    i
    Other names: FPA150, FPA 150
    Associations

    News

    Trials
    Company:
    Amgen
    Drug class:
    B7-H4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over2years
    FPA150-001: FPA150 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=95, Completed, Five Prime Therapeutics, Inc. | Active, not recruiting --> Completed | N=278 --> 95 | Trial completion date: Jan 2022 --> May 2021 | Trial primary completion date: Jan 2022 --> May 2021
    Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    VTCN1 underexpression
    |
    Keytruda (pembrolizumab) • alsevalimab (FPA150)